Breaking News

Hospira Opens New Quality Lab

October 24, 2013

Invests more than $200 million at Rocky Mount, NC plant

Hospira, Inc. has opened a new quality and analytical testing lab at its Rocky Mount, NC. Plant. The company has invested more than $200 million at Rocky Mount, which includes the new quality lab that will have 200 employees responsible for evaluating and testing more than 450 different products. The lab features new technology and advancements in quality and analytical testing and inspection.
 
"Rocky Mount's new laboratory, coupled with our investments throughout the plant, will help ensure that we continue to supply high-quality, more affordable medicines to customers and patients who need them," said Marty Nealey, vice president, Rocky Mount Operations, Hospira. "Through advanced technology and additional space, we've been able to gradually increase our production levels and ensure more consistent release of products, ultimately supporting our ability to provide a more sustainable supply of many life-impacting drugs. I'm very proud of all of the team members here at Rocky Mount and very thankful for the support of this community and our state in furthering our commitment to advancing wellness."
 
"For nearly 80 years, Hospira has been an integral part of the healthcare system, serving hundreds of millions of patients with affordable drugs and delivery systems worldwide," said F. Michael Ball, chief executive officer, Hospira, at today's ceremony. "We are investing more than $1 billion globally to not only serve the patients and hospitals that depend on us with high-quality products in sustainable supply today, but also to make sure that our central role in this system remains vibrant in the future."
 
blog comments powered by Disqus
  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Challenges in Global Biosimilar Development: A Regulatory Perspective

    Challenges in Global Biosimilar Development: A Regulatory Perspective

    Patricia Hurley, Joan Boren and Costantino Congiatu, PPD||June 2, 2015
    More than $60 billion worth of patents on biological products are expiring before 2020, representing a major opportunity for the pharmaceutical industry.